We rank companies based on fund manager, research analyst and news sentiment
AEZS

Aeterna Zentaris
AEZS

$1.95
0.34%
 

About: AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland which generates key revenue, Ireland, Denmark, and others.

Employees: 21

0
Funds holding %
of 6,474 funds
Analysts bullish %
0
News positive %
of 3 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

0.19% less ownership

Funds ownership: 0.92% [Q3] → 0.73% (-0.19%) [Q4]

8% less funds holding

Funds holding: 13 [Q3] → 12 (-1) [Q4]

41% less capital invested

Capital invested by funds: $110K [Q3] → $65.2K (-$45.3K) [Q4]

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4

98% less call options, than puts

Call options by funds: $640 | Put options by funds: $42.6K

Research analyst outlook

1 Wall Street Analyst provided 1 year price forecasts over the past 6 months

Low target
$15
669%
upside
Avg. target
$15
669%
upside
High target
$15
669%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Raghuram Selvaraju
669%upside
$15
Buy
Maintained
13 Nov 2023

Financial journalist opinion

Based on 3 articles about AEZS published over the past 30 days